#Warsaw #Poland #TOOsonix #Consultronix #dermatological therapy

TOOsonix and Consultronix Join Forces to Enhance Dermatological Solutions in Poland

In a significant move for dermatological care in Poland, TOOsonix, a leader in advanced dermatological therapy devices, has officially partnered with Consultronix, a prominent distributor of medical technologies. This strategic collaboration aims to introduce TOOsonix's revolutionary focused ultrasound skin therapy to the Polish healthcare market, catering to a population of over 37 million, many of whom suffer from various skin conditions.

Innovative Solutions for Skin Diseases

The centerpiece of this collaboration is the TOOsonix System ONE-M, a medical device classified as MDR Class IIa and CE-marked, utilizing cutting-edge focused ultrasound technology for effective dermatological treatment. This device offers a non-invasive option for tackling a range of skin diseases, including non-melanoma skin cancers, actinic keratosis, and other common skin ailments. Its design ensures that treatments can be administered swiftly, without the need for anesthesia or downtime—an advantage that is poised to change the landscape of dermal therapies in Poland dramatically.

The efficacy of the System ONE-M is backed by its ability to provide real-time monitoring during treatment, allowing healthcare professionals to assess their approach dynamically. This system stands out in its capacity to deliver targeted ultrasound doses focused directly onto the lesion.

Addressing the Needs of an Aging Population

Given that around 20% of Poland's population is aged 65 and over, this partnership is critical in addressing the specific skincare needs of the aging demographic. With the prevalence of age-related skin diseases on the rise, TOOsonix and Consultronix aim to improve patient care by providing healthcare professionals with state-of-the-art tools to enhance treatment outcomes. The collaboration leverages Consultronix's extensive network across hospitals and private clinics in Poland, ensuring that advanced therapies are readily accessible to those in need.

A Strategic Partnership Strengthening Market Presence

Torsten Bove and Tomasz Zawada, the founders of TOOsonix, expressed their enthusiasm about the partnership, remarking, "We are thrilled to partner with Consultronix to expand our presence in Central Europe. Their deep understanding of the Polish market and commitment to quality make them an ideal partner. Together, we aim to enhance patient outcomes by offering innovative dermatological solutions."

Consultronix, under the leadership of CEO Piotr Smolarski, shares this vision of innovation in dermatological care. Smolarski stated, "We are proud to collaborate with TOOsonix. Their groundbreaking dermatological therapies align perfectly with our mission to equip Polish healthcare professionals with the best tools for addressing evolving patient needs."

A Milestone in International Expansion

This collaboration represents a significant step in TOOsonix's broader international expansion strategy. The company aims to make cutting-edge dermatological therapies available not only across Europe but globally, working alongside respected healthcare partners to ensure effective treatment solutions.

Conclusion

In summary, the partnership between TOOsonix and Consultronix promises to transform the treatment landscape for skin diseases in Poland. With advanced technology at their disposal and a commitment to improving patient care, both companies are set to make a lasting impact on the dermatological field. As they move forward, the goal remains clear: to enhance the quality of care available to those affected by skin challenges across the nation and beyond.

For more information about TOOsonix and its innovative products, visit toosoix.com. For more details about Consultronix, check out consultronix.pl.